

Ref: Syn/CS/SE/Reg 30/2022-23/Aug/12

## **Syngene International Limited**

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India

**T** +91 80 6891 8000 **F** +91 80 6775 8808

www.syngeneintl.com

CIN: L85110KA1993PLC01493

August 27, 2022

То,	То,
The Manager,	The Manager,
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

## <u>Subject: Intimation of incorporation of a wholly owned subsidiary of Syngene International Limited</u> - Syngene Manufacturing Solutions Limited

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(SEBI Listing Regulations), we wish to inform you that Syngene Manufacturing Solutions Limited ("SMSL"), a wholly-owned subsidiary company of the Company has been incorporated on August 26, 2022 under corporate identification number U24290KA2022PLC165409.

The details in respect of SMSL, as required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided in the enclosed Annexure.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

We request you to kindly take same on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Priyadarshini Mahapatra

**Company Secretary and Compliance Officer** 



## **Annexure**

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover, etc.	Name: Syngene Manufacturing Solutions Limited ("SMSL")
		Authorised Capital: 5,00,00,000 equity shares of Rs. 10 /- each aggregating to Rs. 50,00,00,000/-
		Subscribed Capital: 10,00,000 equity shares of Rs. 10 /- each aggregating to Rs. 1,00,00,000/-
		<b>Turnover</b> — Not applicable as it is a newly incorporated Company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is	SMSL will be a related party of Syngene International Limited as it has been incorporated as a wholly owned subsidiary  The Promoters / promoter group / group companies are not interested in the
	done at "arm's length".	transaction.
3	Industry to which the entity being acquired belongs.	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	SMSL shall be engaged in the business of manufacturing of pharmaceutical, biopharmaceutical and biological products of any kind.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition.	Not Applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash
8	Cost of acquisition or the price at which the shares are acquired.	10,00,000 equity shares of Rs. 10/- each aggregating to Rs. 1,00,00,000/-
9	Percentage of shareholding /control acquired and/ or number of shares acquired.	100 per cent
10	Brief background about the entity acquired in terms of products/line of business	Syngene Manufacturing Solutions Limited is a public company incorporated on

Synger
--------

Sr. No.	Particulars	Details
	acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	August 26, 2022 under the provisions of the Companies Act, 2013, under the CIN-U24290KA2022PLC165409, having its registered office in the State of Karnataka. SMSL shall be engaged in the business of manufacturing of pharmaceutical, biopharmaceutical and biological products of any kind.